AstraZeneca shares drop after Pfizer withdraws takeover bid

<p>A planned takeover of AstraZeneca by Pfizer has been scrapped.</p>

The share price of British pharmaceutical company AstraZeneca has fallen heavily this morning (May 27th) after rival firm Pfizer announced it is withdrawing its takeover bid.

The AstraZeneca board was reluctant to do a deal with its rival and Pfizer stated that it will not be pursuing another offer for the company.

AstraZeneca's chairman, Leif Johansson, stated that his firm is going to "continue building on the momentum we have already demonstrated as an independent company."

"We have attractive growth prospects and a rapidly progressing pipeline," he said, adding the company is expecting "positive news flow across our core therapeutic areas" in the coming months.

However, investors responded negatively to the news of the takeover bid dying and shares in AstraZeneca were 1.76 per cent down at 10:04 BST this morning.

Stocks in the pharmaceutical company initially rose by more than ten per cent when news of Pfizer's interest in a takeover of the firm first leaked.

Find up to date information on the FTSE 100 and spread betting strategies at City Index

Build your confidence risk free
Join our live webinars for the latest analysis and trading ideas. Register now

StoneX Financial Ltd (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.

No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

For further details see our full non-independent research disclaimer and quarterly summary.